{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:13:53Z","timestamp":1790072033698,"version":"4.0.1"},"reference-count":17,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"\n Background & objectives:<\/jats:title>\n Prognosis of patients with multiple myeloma (MM) has improved significantly in the past two decades. However, the symptoms burden is high at onset and treatment is generally prolonged with significant financial burden. This study was undertaken to assess the quality of life (QoL) and to analyse out-of-pocket expenditure (OOPE) incurred on MM patients being treated at a tertiary care cancer centre in north India.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This observational, cross-sectional study included 116 patients (aged >18 yr) of MM (both newly diagnosed and those with recurrent disease). For QoL assessment, European Organisation for Research and Treatment of Cancer (EORTC)-validated questionnaire (EORTC QLQ C 30 version 3.0) and disease-specific QLQ MY20 were used. For assessing OOPE incurred on treatment, the National Sample Survey Organisation (NSSO) questionnaire was used.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Bone pains (68.1%), fatigue (59.7%) and dyspnoea (54.6%) were common symptoms. The mean global health status\/QoL score was 59.62\u00b119.21. International Staging System (ISS) score correlated with global health status score, and gastritis was the main adverse effect. QoL score showed negative correlation to side effects of treatment (\u22120.53) of MY20 domain. On multivariate analysis, ISS stage (P<0.001) and adverse effects of treatment (P=0.02) were predictive factors. The median OOPE was <\/jats:p>\n \n \n \n \n \n JOURNAL\/ijmer\/04.03\/02223309-202112000-00010\/math_10MM1\/v\/2022-09-30T185922Z\/r\/image-tiff\n \n \n \n \n <\/jats:p>\n 7900 (IQR, <\/jats:p>\n \n \n \n \n \n JOURNAL\/ijmer\/04.03\/02223309-202112000-00010\/math_10MM2\/v\/2022-09-30T185922Z\/r\/image-tiff\n \n \n \n \n <\/jats:p>\n 4950-13,550) towards medical and <\/jats:p>\n \n \n \n \n \n JOURNAL\/ijmer\/04.03\/02223309-202112000-00010\/math_10MM3\/v\/2022-09-30T185922Z\/r\/image-tiff\n \n \n \n \n <\/jats:p>\n 1150 (IQR, <\/jats:p>\n \n \n \n \n \n JOURNAL\/ijmer\/04.03\/02223309-202112000-00010\/math_10MM4\/v\/2022-09-30T185922Z\/r\/image-tiff\n \n \n \n \n <\/jats:p>\n 500-3100) for non-medical expenses for the past one month.<\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions:<\/jats:title>\n Regular assessment of QoL in the clinical management of multiple myeloma patients has the potential of improving treatment outcomes. Measures to reduce out-of-pocket expenditure may improve treatment compliance.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_4028_20","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T08:55:32Z","timestamp":1654505732000},"page":"823-832","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Quality of life assessment & out-of-pocket expenditure in multiple myeloma"],"prefix":"10.25259","volume":"154","author":[{"given":"Anisha","family":"Mathew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib Hasan","family":"Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-10-20241212","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia \u2013 An Asian myeloma network study","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"R2-10-20241212","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-10-20241212","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canep.2019.02.010","article-title":"Distribution of multiple myeloma in India: Heterogeneity in incidence across age, sex and geography","volume":"59","author":"Bora","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"R4-10-20241212","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-0040-1712792","article-title":"Multiple Myeloma: Front line therapy and autologous stem cell transplantation","volume":"54","author":"Kumar","year":"2018","journal-title":"Ann Natl Acad Med Sci India"},{"key":"R5-10-20241212","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/ijmr.IJMR_1593_18","article-title":"High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome","volume":"149","author":"Kumar","year":"2019","journal-title":"Indian J Med Res"},{"key":"R7-10-20241212","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.7314\/APJCP.2013.14.9.5049","article-title":"Cost of treatment for cancer: Experiences of patients in public hospitals in India","volume":"14","author":"Nair","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"R8-10-20241212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12288-017-0843-7","article-title":"Cost of treatment of multiple myeloma in a public sector tertiary care hospital of north India","volume":"34","author":"Kaur","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R9-10-20241212","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4103\/CRST.CRST_11_19","article-title":"Health-related quality of life in patients with multiple myeloma on novel agents: Report from a tertiary cancer center in rural India","volume":"1","author":"Raghavan","year":"2018","journal-title":"Cancer Res Stat Treat"},{"key":"R15-10-20241212","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2468-2667(19)30019-2","article-title":"Measuring population ageing: An analysis of the global burden of disease study 2017","volume":"4","author":"Chang","year":"2019","journal-title":"Lancet Public Health"},{"key":"R17-10-20241212","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despi\u00e9ge","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R18-10-20241212","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00277-014-2290-y","article-title":"Quality of life in multiple myeloma: Clinical validation of the Mexican-Spanish version of the QLQ-MY20 instrument","volume":"94","author":"Espinoza-Zamora","year":"2015","journal-title":"Ann Hematol"},{"key":"R19-10-20241212","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1049909116646337","article-title":"Self-reported quality of life and symptom burden in ambulatory patients with multiple myeloma on disease-modifying treatment","volume":"34","author":"Kiely","year":"2017","journal-title":"Am J Hosp Palliat Care"},{"key":"R20-10-20241212","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"R21-10-20241212","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: Results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"key":"R22-10-20241212","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: A systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"key":"R23-10-20241212","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: A multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"R24-10-20241212","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bjh.14058","article-title":"The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: Findings from six randomized controlled trials","volume":"174","author":"Robinson","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.IJMR_4028_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:04:38Z","timestamp":1751497478000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/quality-of-life-assessment-out-of-pocket-expenditure-in-multiple-myeloma-an-observational-study\/"}},"subtitle":["An observational study"],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_4028_20","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}